Acist, HealthTrust ink three year deal

Contrast delivery developer Acist Medical Systems and HealthTrust, a healthcare group purchasing organization, have entered into a three-year contract for the company's cardiovascular injection technology.

The agreement gives HealthTrust members including hospitals, clinicians and other staff access to the Acist CVi contrast injection system, according to the Eden Prairie, Minn.-based company. The CVi variable flow-rate injection system provides a method of contrast injection during cardiac and vascular angiography procedures that alleviates the use of stopcocks, syringes and tubing.

According to Acist, the three-year contract became effective Dec. 1, 2009.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.